These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30470264)

  • 1. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.
    Zacher A; Kaulich K; Stepanow S; Wolter M; Köhrer K; Felsberg J; Malzkorn B; Reifenberger G
    Brain Pathol; 2017 Mar; 27(2):146-159. PubMed ID: 26919320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations.
    Parilla M; Kadri S; Patil SA; Fitzpatrick C; Ritterhouse L; Segal J; Collins J; Pytel P
    J Neuropathol Exp Neurol; 2019 Mar; 78(3):257-267. PubMed ID: 30698790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.
    Sahm F; Schrimpf D; Jones DT; Meyer J; Kratz A; Reuss D; Capper D; Koelsche C; Korshunov A; Wiestler B; Buchhalter I; Milde T; Selt F; Sturm D; Kool M; Hummel M; Bewerunge-Hudler M; Mawrin C; Schüller U; Jungk C; Wick A; Witt O; Platten M; Herold-Mende C; Unterberg A; Pfister SM; Wick W; von Deimling A
    Acta Neuropathol; 2016 Jun; 131(6):903-10. PubMed ID: 26671409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Classification of gliomas. Current progress and perspectives].
    Capper D; Reifenberger G
    Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors.
    Carter JH; McNulty SN; Cimino PJ; Cottrell CE; Heusel JW; Vigh-Conrad KA; Duncavage EJ
    J Mol Diagn; 2017 Mar; 19(2):328-337. PubMed ID: 28042970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.
    Dubbink HJ; Atmodimedjo PN; van Marion R; Krol NMG; Riegman PHJ; Kros JM; van den Bent MJ; Dinjens WNM
    J Mol Diagn; 2016 Sep; 18(5):775-786. PubMed ID: 27461031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of immunohistochemistry in the diagnosis of molecular genetic alterations in central nervous system gliomas: Next-generation sequencing of 212 mutations in 112 patients.
    Daoud EV; Chkheidze R; Yell PC; Hatanpaa KJ; Raisanen JM; Cai C
    Clin Neuropathol; 2022; 41(1):35-40. PubMed ID: 34672256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?
    Kam KL; Appin CL; Mao Q; Ikegami S; Lukas RV; Nikiforova MN; Roy S; Brat DJ; Horbinski C
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):763-766. PubMed ID: 32483596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
    Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
    [No Abstract]   [Full Text] [Related]  

  • 18. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
    Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
    Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.
    Śledzińska P; Bebyn M; Szczerba E; Furtak J; Harat M; Olszewska N; Kamińska K; Kowalewski J; Lewandowska MA
    Mol Diagn Ther; 2022 Nov; 26(6):699-713. PubMed ID: 36053463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis.
    Zeng C; Wang J; Li M; Wang H; Lou F; Cao S; Lu C
    Cancer Manag Res; 2021; 13():3573-3588. PubMed ID: 33953611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.